Trial
NCT02269579
Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Jazz Pharmaceuticals
Collaborators
—
Condition
Acute Myeloid Leukemia (AML)
Intervention
CPX-351
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-03-14